down arrow

Caplin Point Lab

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE475E01026
  • NSEID: CAPLIPOINT
  • BSEID: 524742
INR
1,829.95
114.95 (6.7%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 2.98 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Caplin Point Laboratories Ltd stock-summary
stock-summary
Caplin Point Laboratories Ltd
Mid Cap
Pharmaceuticals & Drugs
Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
Company Coordinates stock-summary
Company Details
Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat Chennai Tamil Nadu : 600096
stock-summary
Tel: 91-44-24968000/71148000/28156653
stock-summary
investor@caplinpoint.net/info@capli
Registrar Details
Integrated Enterprises (India) Ltd , II Floor , Kences Towers, No 1 Ramakrishna Street, North Usman Road, T Nagar, Chennai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 15.20 Cr
Number of Shares
7.6 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
16-Jul-2024
7.6
15.20
1400
2
Issued under ESOP Scheme
19-Jun-2024
7.6
15.20
68550
2
Issued under ESOP Scheme
21-Dec-2023
7.59
15.19
1000
2
Issued under ESOP Scheme
11-Oct-2023
7.59
15.19
1000
2
Issued under ESOP Scheme
11-Sep-2023
7.59
15.19
6000
2
Issued under ESOP Scheme
05-Jun-2023
7.59
15.19
12000
2
Issued under ESOP Scheme
11-Apr-2023
7.59
15.18
19000
2
Issued under ESPS
11-Apr-2023
7.59
15.18
19000
2
Issued under ESPS
17-Feb-2023
7.59
15.18
5000
2
Issued under ESOP Scheme
04-Jan-2023
7.59
15.18
5500
2
Issued under ESOP Scheme
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 16 Schemes (1.86%)

FIIs

Held by 126 FIIs (4.86%)

Promoter with highest holding

P Vijayalakshmi (24.71%)

Highest Public shareholder

Uti Small Cap Fund (1.39%)

Individual Investors Holdings

15.77%

stock-summary Board of Directors
stock-summary
stock-summary
Management
Designation
Remuneration
C C Paarthipan
Chairman & Non Executive Dir.
0
D Sathyanarayanan
Independent Non Exe. Director
1.6 lacs
C K Gariyali
Independent Director
1.0 lacs
Deenadayalan Singaram
Independent Non Exe. Director
60.0 k
R Nagendran
Independent Non Exe. Director
40.0 k
Sridhar Ganesan
Non Independent Executive Dire
87.0 lacs
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Export Incentives
15.75
2.93%
 
2.93
Export Incentives
97.07
Export Incentives
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
493 Cr
(Quarterly Results - Dec 2024)
Net Profit:
139 Cr
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 13,910 Cr (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.29%

stock-summary
Debt Equity

-0.32

stock-summary
Return on Equity

19.41%

stock-summary
Price to Book

5.13